Burlington, Mass.– PharmaEssentia USA Corporation will unveil new clinical data highlighting the promise of its investigational therapies for myeloproliferative neoplasms (MPNs) during the 2025 European Hematology Association (EHA) Congress in Milan, Italy, from June 12–15.
Leading the company’s presence is a plenary presentation of results from the Phase 3 SURPASS-ET trial evaluating ropeginterferon alfa-2b-njft for the treatment of essential thrombocythemia (ET). The study was selected as one of just six top-tier abstracts by the EHA Scientific Program Committee, underscoring its scientific significance.
The plenary session will feature Dr. Harry Gill, hematologist and oncologist at the University of Hong Kong, who will present the data comparing ropeginterferon alfa-2b to anagrelide. According to earlier topline results, the therapy achieved a significantly higher durable clinical response rate—42.9% compared to 6.0% with anagrelide (p=0.0001)—along with a favorable safety profile and a more pronounced reduction in JAK2 V617F allelic burden over 12 months.
“I’m deeply honored that the SURPASS-ET study was chosen for plenary presentation,” said Dr. Gill. “These results could mark an important shift in how we treat ET and offer real hope to patients.”
In addition to the ET findings, Dr. Gill will present new data from a Phase 2 trial assessing the use of ropeginterferon alfa-2b in patients with pre-fibrotic primary myelofibrosis (PMF) and low-to-intermediate risk myelofibrosis under the Dynamic International Prognostic Scoring System (DIPSS). This presentation will be part of an oral session on emerging therapies for MPNs.
PharmaEssentia’s investigational therapy ropeginterferon alfa-2b is already approved for polycythemia vera and is being studied for broader use across other MPNs.
“Ropeginterferon alfa-2b continues to demonstrate its potential to transform care across the spectrum of MPNs,” said Dr. Ko-Chung Lin, Founder and CEO of PharmaEssentia USA. “These new data help reinforce our commitment to expanding innovative treatment options for patients living with these chronic blood cancers.”
